LMF
CASC

LMR Master Fund’s Cascadian Therapeutics, Inc. CASC Stock Holding History

LMR Master Fund’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		$44K Buy
+4,184
New +$46.8K ﹤0.01% 337
2013
Q3 		– Sell
-30,992
Closed -$290K – 479
2013
Q2 		$290K Buy
+30,992
New +$398K 0.03% 332

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ERSOT
Employees Retirement System of Texas Austin, Texas $11.4B AUM 21.6% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

LMR Master Fund's CASC Position: Q4 2013 in Review

LMR Master Fund opened a new position in Cascadian Therapeutics, Inc. (CASC) in Q4 2013: 4,184 shares worth $44K. The stake represents ﹤0.01% of the portfolio and ranks #337 among its holdings. This is a return to the name: LMR Master Fund previously reported a position in CASC as recently as Q2 2013.

LMR Master Fund first reported a position in CASC in Q2 2013 and has held it in 2 quarters since. The position peaked at $290K in Q2 2013. 67 funds tracked by Wall St. Rank hold CASC as of Q4 2013.

  • LMR Master Fund held 4,184 shares of Cascadian Therapeutics, Inc. worth $44K as of Q4 2013.
  • Cascadian Therapeutics, Inc. was a new LMR Master Fund position in Q4 2013.
  • Cascadian Therapeutics, Inc. made up ﹤0.01% of LMR Master Fund's portfolio in Q4 2013, its #337 holding.
  • LMR Master Fund first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and has held it in 2 quarters since.
  • LMR Master Fund's Cascadian Therapeutics, Inc. position peaked at $290K in Q2 2013.
  • 67 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q4 2013.

Based on LMR Master Fund's 13F filing for Q4 2013, filed 14 Feb 2014.